Ameliorative effects of Gly[14]-humanin on cyclophosphamide-induced premature ovarian insufficiency and underlying mechanisms.

Huang J, Liu Y, Zou L, Zhu C, Xia W

Reproductive biomedicine online7 Mar 2025

PMID40639309DOI10.1016/j.rbmo.2025.104901PepBankPUB-40639309

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with cyclophosphamide-induced premature ovarian insufficiency, HNG restored the disrupted oestrous cycle.
In plain wordsIn rats with chemotherapy-induced ovarian damage, a Humanin analogue (HNG) restored the disrupted oestrous cycle.
Peptide
Humanin
Outcome
IncreaseOestrous cycle regularity
Study
ratn: not reported in source
cyclophosphamide-induced premature ovarian insufficiency
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intraperitonealAs given in this study (rat).
Source sentences
Summary
restoring the disrupted oestrous cycle and sex hormone concentrations
1 context sentence(design, population, supporting numbers)
Summary · context
A POI model was induced in female rats by intraperitoneal injection of cyclophosphamide, followed by treatment with an intraperitoneal injection of HNG.
Report a problemFND-4063930901
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with cyclophosphamide-induced premature ovarian insufficiency, HNG restored the disrupted sex hormone concentrations.
In plain wordsIn rats with chemotherapy-induced ovarian damage, a Humanin analogue (HNG) restored disrupted sex hormone levels.
Peptide
Humanin
Outcome
MixedSex hormone concentrations
Study
ratn: not reported in source
cyclophosphamide-induced premature ovarian insufficiency
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intraperitonealAs given in this study (rat).
Source sentences
Summary
restoring the disrupted oestrous cycle and sex hormone concentrations
1 context sentence(design, population, supporting numbers)
Summary · context
A POI model was induced in female rats by intraperitoneal injection of cyclophosphamide, followed by treatment with an intraperitoneal injection of HNG.
Report a problemFND-4063930902
03AnimalAnimal study (in vivo)Efficacy outcome
In rats with cyclophosphamide-induced premature ovarian insufficiency, HNG reduced follicular depletion (P < 0.05).
In plain wordsIn rats with chemotherapy-induced ovarian damage, a Humanin analogue (HNG) reduced the loss of follicles.
Peptide
Humanin
Outcome
DecreaseFollicular depletion
Study
ratn: not reported in source
cyclophosphamide-induced premature ovarian insufficiency
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intraperitonealAs given in this study (rat).
Source sentences
Summary
reducing follicular depletion (P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
A POI model was induced in female rats by intraperitoneal injection of cyclophosphamide, followed by treatment with an intraperitoneal injection of HNG.
Report a problemFND-4063930903
04AnimalAnimal study (in vivo)Efficacy outcome
In rats with cyclophosphamide-induced premature ovarian insufficiency, HNG reduced apoptosis (P < 0.001).
In plain wordsIn rats with chemotherapy-induced ovarian damage, a Humanin analogue (HNG) reduced cell death in the ovary.
Peptide
Humanin
Outcome
DecreaseOvarian apoptosis
Study
ratn: not reported in source
cyclophosphamide-induced premature ovarian insufficiency
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · intraperitonealAs given in this study (rat).
Source sentences
Summary
apoptosis (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A POI model was induced in female rats by intraperitoneal injection of cyclophosphamide, followed by treatment with an intraperitoneal injection of HNG.
Report a problemFND-4063930904
05LabIn vitro (cells)Efficacy outcome
In COV434 granulosa cells, HNG treatment enhanced cell viability (P < 0.01).
In plain wordsIn cells, a Humanin analogue (HNG) raised the number of living ovarian cells.
Peptide
Humanin
Outcome
IncreaseCell viability
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
HNG treatment enhanced cell viability (P < 0.01)
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930905
06LabIn vitro (cells)Safety outcome
In COV434 granulosa cells, HNG treatment did not cause abnormal cell proliferation.
In plain wordsIn cells, a Humanin analogue (HNG) did not cause abnormal cell growth.
Peptide
Humanin
Outcome
No significant changeAbnormal cell proliferation
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
without causing abnormal cell proliferation.
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930906
07LabIn vitro (cells)Efficacy outcome
In COV434 granulosa cells damaged by 4-HC, HNG increased expression of the proliferation markers EdU and Ki67 (P < 0.05).
In plain wordsIn cells damaged by a chemotherapy metabolite, a Humanin analogue (HNG) raised markers of cell growth.
Peptide
Humanin
Outcome
IncreaseProliferation markers EdU and Ki67
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Organ injury · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
increasing the expression of proliferation markers (EdU and Ki67) and reducing ROS and mtROS concentrations (P < 0.05)
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930907
08LabIn vitro (cells)Mechanism
In COV434 granulosa cells damaged by 4-HC, HNG reduced ROS and mitochondrial ROS concentrations (P < 0.05).
In plain wordsIn cells damaged by a chemotherapy metabolite, a Humanin analogue (HNG) lowered reactive oxygen species.
Peptide
Humanin
Outcome
DecreaseROS and mitochondrial ROS
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Mitochondrial function · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
reducing ROS and mtROS concentrations (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930908
09LabIn vitro (cells)Mechanism
In COV434 granulosa cells, HNG decreased the 4-HC-induced elevation in Bax expression (P < 0.05).
In plain wordsIn cells, a Humanin analogue (HNG) lowered a cell-death protein (Bax) that the chemotherapy metabolite had raised.
Peptide
Humanin
Outcome
DecreaseBax expression
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
HNG also decreased the 4-HC-induced elevation in Bax expression
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930909
10LabIn vitro (cells)Mechanism
In COV434 granulosa cells, HNG increased the expression of Bcl-2 (P < 0.05).
In plain wordsIn cells, a Humanin analogue (HNG) raised a cell-survival protein (Bcl-2).
Peptide
Humanin
Outcome
IncreaseBcl-2 expression
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
increased the expression of Bcl-2 and phosphorylated STAT3 (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930910
11LabIn vitro (cells)Mechanism
In COV434 granulosa cells, HNG increased the expression of phosphorylated STAT3 (P < 0.05).
In plain wordsIn cells, a Humanin analogue (HNG) raised the active form of the STAT3 signalling protein.
Peptide
Humanin
Outcome
IncreasePhosphorylated STAT3 expression
Study
humann: not reported in source
COV434 granulosa cells exposed to 4-HC
Outcome group
Receptor activity and mechanism · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
increased the expression of Bcl-2 and phosphorylated STAT3 (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
The human ovarian granulosa cell line COV434 was exposed to the cyclophosphamide metabolite 4-hydroperoxy cyclophosphamide (4-HC), followed by HNG treatment.
Report a problemFND-4063930911

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.